Maze Therapeutics, Inc. (MAZE) Total Return Calculator with Dividends Reinvested

Maze Therapeutics, Inc.

Popular:

The total return for Maze Therapeutics, Inc. (MAZE) stock is +88.50% over the past 12 months. So far it's down 39.43% this year. The 5-year total return is +51.03%, meaning $10,000 invested in MAZE stock 5 years ago would be worth $15,103 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in MAZE 1 year ago, it would be worth $17,779 today — you'd have gained $7,779.

With Dividends Reinvested$17,779+77.79%

Price Only (No DRIP)$17,779+77.79%

Period2025-06-12 → 2026-06-11

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in MAZE

1Y$18,850+$8,850 (+88.5%)88.5% CAGR

3Y$15,103+$5,103 (+51.0%)14.7% CAGR

5Y$15,103+$5,103 (+51.0%)8.6% CAGR

10Y$15,103+$5,103 (+51.0%)4.2% CAGR

15Y$15,104+$5,104 (+51.0%)2.8% CAGR

20Y$15,103+$5,103 (+51.0%)2.1% CAGR

30Y$15,103+$5,103 (+51.0%)1.4% CAGR

Maze Therapeutics, Inc. did not pay dividends during this period. Total return = price return.

Loading MAZE total return...

As of 2026-06-12

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-39.43%	—	-39.43%	—	$6,057
1Y	+88.50%	88.50%	+88.50%	—	$18,850
3Y	+51.03%	14.73%	+51.03%	—	$15,103
5Y	+51.03%	8.60%	+51.03%	—	$15,103
10Y	+51.03%	4.21%	+51.03%	—	$15,103
15Y	+51.04%	2.79%	+51.04%	—	$15,104
20Y	+51.03%	2.08%	+51.03%	—	$15,103
30Y	+51.03%	1.38%	+51.03%	—	$15,103

Risk & Highlights

Best Year+159.75%2025

Max Drawdown-53.18%2026-03-12 → 2026-06-08

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	+14.63%	+14.63%	—	+0.41%	+14.2pp
2025	+159.75%	+159.75%	—	+16.64%	+143.1pp

MAZE outperformed the S&P 500 by 65.82pp over the past year (+88.50% vs +22.68%).

Loading summary...

MAZE Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
MAZEMaze Therapeutics, Inc.	$1.3B	-5.6%	-39.4%	+88.5%	—	+51.0%	+51.0%	+51.0%
RAREUltragenyx Pharmaceutical Inc.	$2.4B	-8.8%	+1.6%	-36.1%	—	-53.3%	-76.4%	-60.0%
FOLDAmicus Therapeutics, Inc.	$4.5B	—	+1.5%	+136.0%	—	+11.6%	+36.4%	+147.3%
ACMRACM Research, Inc.	$6.1B	+41.8%	+104.3%	+254.7%	—	+770.8%	+209.9%	+4803.7%
BEAMBeam Therapeutics Inc.	$3.0B	-7.4%	+8.4%	+64.4%	—	-10.8%	-66.9%	+56.9%
NTLAIntellia Therapeutics, Inc.	$1.4B	-14.4%	+34.1%	+47.6%	—	-71.7%	-85.5%	-53.6%
ARWRArrowhead Pharmaceuticals, Inc.	$10.5B	-4.3%	+9.8%	+344.5%	—	+110.3%	-16.1%	+1167.6%
ALNYAlnylam Pharmaceuticals, Inc.	$38.6B	+1.6%	-27.7%	-3.1%	—	+49.9%	+75.4%	+377.1%
IONSIonis Pharmaceuticals, Inc.	$12.2B	-2.1%	-7.3%	+104.0%	—	+77.3%	+94.6%	+243.8%
KRYSKrystal Biotech, Inc.	$9.5B	+2.8%	+30.2%	+130.3%	—	+148.8%	+394.3%	+2922.0%
PTCTPTC Therapeutics, Inc.	$6.2B	-2.8%	-2.6%	+47.0%	—	+72.3%	+73.9%	+989.1%

Compare:MAZE vs RARE MAZE vs FOLD MAZE vs ACMR MAZE vs RARE vs FOLD

About MAZE Dividend Returns

Maze Therapeutics, Inc. (MAZE) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of MAZE over the past year?

Maze Therapeutics, Inc. (MAZE) delivered a return of 88.50% over the past year. Since MAZE does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in MAZE be worth today?

A $10,000 investment in Maze Therapeutics, Inc. one year ago would be worth $18,850 today, representing a gain of $8,850.

Q3Does MAZE pay dividends?

Maze Therapeutics, Inc. (MAZE) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For MAZE, the total return equals the price-only return.

Q4Did MAZE beat the S&P 500?

Yes, Maze Therapeutics, Inc. (MAZE) outperformed the S&P 500 by 65.82 percentage points over the past year. MAZE delivered a total return of 88.50%, compared to the S&P 500's 22.68%. This 65.82pp alpha means investors in MAZE earned more than a passive S&P 500 index fund.

Q5What is MAZE's worst drawdown?

Maze Therapeutics, Inc. (MAZE) experienced a maximum drawdown of -53.18% over the past year, declining from its peak on 2026-03-12 to its trough on 2026-06-08. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is MAZE's long-term total return over 10, 20, or 30 years?

Here are Maze Therapeutics, Inc. (MAZE)'s long-term returns with dividends reinvested. Over 10 years, the total return is 51.0% (4.2% CAGR) — $10,000 would have grown to $15,103. Over 20 years: 51.0% total return (2.1% CAGR) — $10,000 → $15,103. Over 30 years: 51.0% total return (1.4% CAGR) — $10,000 → $15,103. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

How much would $100/month in MAZE be worth today?

Dollar cost averaging calculator · DCA vs lump sum · see how regular investing compounds

Run the Numbers →